Clinical Policy: Lebrikizumab-lbkz (Ebglyss)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PCH.58 alerts
Get alerted when Policy CP.PCH.58 changes without checking for updates manually.
Monitor payer policy activity
This policy governs commercial and HIM/ICHRA prior authorization coverage for Ebglyss used to treat moderate-to-severe atopic dermatitis in eligible members. It defines initial and continued-therapy criteria, dosing limits, documentation requirements, exclusions, and referral rules for other uses.
The 4Q 2026 annual review added every-8-week maintenance dosing as an option for initial and continued therapy in accordance with the prescribing information.
The 4Q 2026 annual review added Nemluvio as an example of a biologic medication for which concurrent use is excluded.
The original policy added redirection to preferred agents Dupixent or Rinvoq in the atopic dermatitis initial approval criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.